For example, participants in clinical trials of semaglutide lost an average of 15% of their body weight, compared to 2-4% in placebo groups
Current law prohibits Medicare from covering obesity drugs and gives states flexibility to cover weight loss drugs under Medicaid Limitations on coverage for obesity drugs in Medicare and Medicaid mean that millions of people who have obesity and might benefit from taking GLP-1s may be unable to access them unless they are able to pay the full cash price out of their own pockets, which would likely be prohibitive for people with Medicaid who must have low incomes to qualify for the program, as well as for many people on Medicare with low and modest incomes
But it almost certainly reduces the gastrointestinal rebound effects that some researchers report after abrupt cessation, including paradoxical increases in appetite, changes in bowel habits, and blood sugar fluctuations
These medications work by mimicking the action of naturally occurring GLP-1, an incretin hormone released by the intestines in response to food intake
Thats a potential liability, Upadhye explained
A prospective study demonstrated that 12 weeks of liraglutide treatment produced significant PASI score reductions from 15.7 to 2.2 and improved DLQI scores from 21.8 to 4.1 [60]
